Presentations:

IFX-1 in patients with moderate to severe hidradenitis suppurativa /acne inversa (HS): baseline characteristics of a double-blind, randomized phase 2b dose-finding study (SHINE)

Presenter:

Evangelos J Giamarellos-Bourboulis (Athens, Greece)

Date:

Friday, Feb 8, 2019

Time:

4:00pm – 4:15pm CET

Download Presentation

Long term results from a phase 2a clinical study with IFX-1 in severe hidradenitis suppurativa

Presenter:

Evangelos J Giamarellos-Bourboulis (Athens, Greece)

Date:

Friday, Feb 8, 2019

Time:

4:15pm – 4:30pm CET

Download Presentation